Hearing News Watch

BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF,

WASHINGTON, D.C. — National Institutes of Health researchers have discovered a specific network of proteins that is necessary to restore hearing in zebrafish through cell regeneration. The study, led by investigators at the National Human Genome Research Institute (NHGRI), may inform the development of treatments for hearing loss in humans. The findings were published in Cell Genomics. Although hair cell loss cannot

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation. At the beginning of 2021,

FRANKFURT/MAINZ — The 66th International Congress of Hearing Aid Acousticians (EUHA) and the accompanying Industry Exhibition will provide insights into innovations in the field of hearing on October 12, 2022. More than 25 top-class expert lectures, five tutorials, and four forward-looking Future  Friday lectures will be on offer for participants. In addition, they will debut the EUHA  Science Symposium on

TOKYO AND LYNGE, DENMARK — Sony Corporation and WS Audiology Denmark A/S have entered into a partnership agreement and various ancillary agreements with the aim of jointly developing and supplying new products and services in the over-the-counter self-fitting hearing aid market, beginning with the United States. Through the partnership, Sony and WSA will combine their respective technological and medical expertise to create

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage  biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion on Sensorion’s application for Orphan Drug Designation (ODD) for its

Andrew Bellavia has today announced the launch of a new consulting business, AuraFuturity, to serve the hearing health and related hearables markets. Focusing on go-to-market, branding, and content, AuraFuturity is positioned to assist innovators to define their value and communicate it effectively to their target customers.  “Untreated hearing loss is a global pandemic with more than 1.5 billion people affected,

SOMERSET, NEW JERSEY — More than 2,500 hearing care professionals registered for the knowledge-sharing Oticon Own™ launch event, including a live audience at Oticon US headquarters in Somerset, NJ who joined alongside virtual participants from across the US. The launch event introduced Oticon Own™, the world’s first custom hearing aid with an on-board Deep Neural Network* (DNN). Oticon President Gary

WASHINGTON D.C.  — Otolith Labs, a medical technology company developing noninvasive wearable medical devices for the treatment of vestibular disorders, announced the closing of a $20 million Series A financing round by Morningside Ventures. Building on prior investments from businessman Mark Cuban and leading ENT physicians, the proceeds will be used to support the company’s ongoing clinical programs, anticipated FDA

BOSTON, MASSACHUSSETTS — An artificial-intelligence (AI) model built at Mass Eye and Ear was shown to be significantly more accurate than doctors at diagnosing pediatric ear infections in the first head-to-head evaluation of its kind, a research team working to develop the model for clinical use reported. According to a new study published August 16 in Otolaryngology–Head and Neck Surgery, the model,